Additional file 1 of Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus

Additional file 1: Table S1. Cardiovascular disease at baseline (by medical condition). Data are number of patients (% from subgroup). Table S2. LDL-C levels over time of the overall cohort and by PCSK9 inhibitor agent (A) and according to diabetes status (B). Data are median (IQR). *P-values were calculated by using the Wilcoxon signed-rank test and refers to the comparisons of laboratory data between baseline and defined time-point. Table S3. Triglyceride levels over time of the overall cohort and by PCSK9 inhibitor (A) and according to diabetes status (B). Data are median (IQR). *P-values were calculated by using the Wilcoxon signed-rank test and refers to the comparisons of laboratory data between baseline and defined time-point. Table S4. HDL cholesterol levels over time of the overall cohort and by PCSK9 inhibitor agent (A) and diabetes status (B). Data are median (IQR). *P-values were calculated by using the Wilcoxon signed-rank test and refers to the comparisons of laboratory data between baseline and defined time-point. Table S5. Lipoprotein(a) levels and follow-up measurement of the overall cohort, by PCSK9 inhibitor agent and by diabetes status. Data are median (IQR). *P-values were calculated by using the Wilcoxon signed-rank test and refers to the comparisons of laboratory data between baseline and defined time. Only patients with follow-up data for Lp(a) were included in the analysis. † First performed follow-up measurement after initiation of PCSK9 inhibitor therapy was included in the analysis. Table S6. HbA1c levels over time of the overall cohort, without and with diabetes mellitus at baseline. Data are median (IQR). * P-values were calculated by using the Wilcoxon signed-rank test and refers to the comparisons of laboratory data between baseline and defined time-point.